Many companies have foreshadowed deals to come during earnings calls in recent days. The return of M&A would be a welcome ...

WASHINGTON (AP) — U.S. economy shrinks by 0.3% in first quarter of 2025, first drop in three years as Trump trade wars disrupt businesses.

Sullivan & Cromwell is acting for longtime client Merck in its $3.9bn acquisition of US biotech company SpringWorks ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Summit Therapeutics (SMMT – Research Report) and Altimmune (ALT – Research Rep ...

The official survey by the China Federation of Logistics and Purchasing shows export orders slowed in April, with Beijing and ...

HONOLULU (AP) — In a first-of-its kind move, Hawaii lawmakers are ready to hike a tax imposed on travelers staying in hotels, ...

PANHANDLE, Texas (AP) — After his inauguration, President Donald Trump issued a series of orders ending legal pathways for ...

Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

Germany’s Merck KGaA has agreed to acquire U.S. biotech SpringWorks Therapeutics for $3.9 billion. The acquisition, aimed at ...

Fintel reports that on April 29, 2025, Guggenheim downgraded their outlook for SpringWorks Therapeutics (NasdaqGS:SWTX) from ...

Barely a year after the U.S. FDA shackled Abeona Therapeutics Inc.’s cell-based gene therapy with a complete response letter, the agency has approved it for treating a rare and genetic skin disease.

Merck KGaA said the deal will grow its U.S. presence and expand the reach of SpringWorks’ drugs, including one approved in February.